Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

20151,210 citationsJournal Articlebronze Open Access

Authors

Toni K. Choueiri · Prostate Cancer Research

Bernard Escudier · Institut Gustave Roussy

Thomas Powles · Cancer Research UK

Paul N. Mainwaring · Cancer Council Queensland

Brian I. Rini · Cleveland Clinic

Frede Donskov · Aarhus University Hospital

Hans J. Hammers ·

Abstract

Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 19, pp. 1814-1823

DOI: 10.1056/nejmoa1510016

Field-Weighted Citation Impact: 115.97